The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - Avanir Pharmaceuticals (AVNR) added $400 million to its valuation on Monday morning with positive results from a phase 2 trial evaluating the safety and efficacy of AVP-923 in Alzheimer’s … Continue Reading
Read nowRecap - A dual event in the obesity space this week, the U.S. FDA approved Orexigen Therapeutics’ (OREX) weight loss pill Contrave just one day before an … Continue Reading
Read nowResearch - We’ve considered Medivation (MDVN) a long-term play on the clinical and commercial strength of XTANDI (enzalutamide), which with the aid of Astellas (ALPMY) is well on its way toward … Continue Reading
PremiumInsights - Hyperion Therapeutics (HPTX) shuttered development of DiaPep277 in newly diagnosed Type 1 diabetes on Monday, citing improper trial conduct from the drug’s original developer, Andromeda Biotech. Hyperion acquired … Continue Reading
Read nowResearch - Orexigen Therapeutics (OREX) is trading at $6.00 this afternoon, one week ahead of the September 11 FDA approval decision for Contrave (NB32). We suggested buying OREX in late July at $5.20 as … Continue Reading
PremiumResearch - For long-term PropThink subscribers, few investments have yielded higher profits than Illumina (ILMN). Since our initiation of coverage in November 2012, shares of the San Diego-based company … Continue Reading
Premium
